Literature DB >> 22946873

Improving clinical outcomes for naltrexone as a management of problem alcohol use.

Gary K Hulse1.   

Abstract

Despite being a relatively effective and safe treatment, the clinical management of alcohol abuse/dependence by oral naltrexone can be compromised due to the patient's non-compliance with daily use of this medication. Over the past decade an increasing body of research has suggested that the use of sustained release depot naltrexone preparations can overcome this issue and deliver improved clinical outcomes. However, at the same time, research findings from diverse areas of pharmacogenetics, neurobiology and behavioural psychology have also been converging to identify variables including genetic markers, patient psychosocial characteristics and drug use history differences, or clusters of these variables that play a major role in mediating the response of alcohol abuse/dependent persons to treatment by naltrexone. While this article does not attempt to review all available data pertaining to an individual alcohol dependent patient's response to treatment by naltrexone, it does identify relevant research areas and highlights the importance of data arising from them. The characterization of clinical markers, to identify those patients who are most likely to benefit from naltrexone and to tailor a more individual naltrexone treatment, will ultimately provide significant benefit to both patients and clinicians by optimizing treatment outcome.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Keywords:  alcoholism; clinical subtypes; naltrexone maintenance; oral naltrexone; pharmacogenetics; pharmacokinetics; predictors of treatment outcomes

Mesh:

Substances:

Year:  2013        PMID: 22946873      PMCID: PMC3853523          DOI: 10.1111/j.1365-2125.2012.04452.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  73 in total

1.  Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.

Authors:  J Gelernter; H Kranzler; J Cubells
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

Review 2.  Intramuscular extended-release naltrexone: current evidence.

Authors:  David R Gastfriend
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

3.  Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

Authors:  Stephanie S O'Malley; James C Garbutt; David R Gastfriend; Qunming Dong; Henry R Kranzler
Journal:  J Clin Psychopharmacol       Date:  2007-10       Impact factor: 3.153

4.  Naltrexone and alcohol dependence. Role of subject compliance.

Authors:  J R Volpicelli; K C Rhines; J S Rhines; L A Volpicelli; A I Alterman; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1997-08

5.  Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.

Authors:  S J Porter; A A Somogyi; J M White
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

6.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

7.  Adverse effects of oral naltrexone: analysis of data from two clinical trials.

Authors:  C Oncken; J Van Kirk; H R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

8.  Sustained-release naltrexone for alcoholism treatment: a preliminary study.

Authors:  H R Kranzler; V Modesto-Lowe; E S Nuwayser
Journal:  Alcohol Clin Exp Res       Date:  1998-08       Impact factor: 3.455

9.  Early treatment response in alcohol dependence with extended-release naltrexone.

Authors:  Domenic A Ciraulo; Qunming Dong; Bernard L Silverman; David R Gastfriend; Helen M Pettinati
Journal:  J Clin Psychiatry       Date:  2008-02       Impact factor: 4.384

10.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more
  5 in total

1.  Drugs for addiction: a therapeutic area in need of a 'shot in the arm'.

Authors:  Andrea L Malizia; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 2.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

3.  Effects of Naltrexone on Expression of Lipid Metabolism-Related Proteins in Liver Steatosis Induced by Endoplasmic Reticulum Stress in Mice.

Authors:  Ping Yang; Leyao Xiao; Fei Zhao; Wei He; Guijuan Zhang; Yongjing Tang; Yinghua Chen; Qijiao Cheng; Yihuai He
Journal:  Contrast Media Mol Imaging       Date:  2022-05-29       Impact factor: 3.009

4.  New Biodegradable Poly(l-lactide)-Block-Poly(propylene adipate) Copolymer Microparticles for Long-Acting Injectables of Naltrexone Drug.

Authors:  Stavroula Nanaki; Athina Viziridou; Alexandra Zamboulis; Margaritis Kostoglou; Georgios Z Papageorgiou; Dimitrios N Bikiaris
Journal:  Polymers (Basel)       Date:  2020-04-07       Impact factor: 4.329

5.  Amphiphilic Block Copolymer Microspheres Derived from Castor Oil, Poly(ε-carpolactone), and Poly(ethylene glycol): Preparation, Characterization and Application in Naltrexone Drug Delivery.

Authors:  Maria Nerantzaki; Eirini Skoufa; Kyriakos-Vasileios Adam; Stavroula Nanaki; Apostolos Avgeropoulos; Margaritis Kostoglou; Dimitrios Bikiaris
Journal:  Materials (Basel)       Date:  2018-10-16       Impact factor: 3.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.